Relugolix (Orgovyx)
Overview
Relugolix is an orally bioavailable non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist. Although it is not a peptide, it exerts its therapeutic effect through the same mechanism as peptide GnRH antagonists, competitively blocking pituitary GnRH receptors to suppress gonadotropin and sex steroid production. It is indicated for advanced prostate cancer and, in combination formulation, for management of heavy menstrual bleeding associated with uterine fibroids and moderate to severe endometriosis pain. The oral route of administration offers a distinct advantage over depot peptide formulations.
Key Research Findings
Relugolix received FDA approval in 2020 for advanced prostate cancer based on the HERO trial (NEJM 2020), which demonstrated sustained castration in 96.7% of patients compared to 88.8% on leuprolide, with a significantly lower risk of major adverse cardiovascular events. In 2021, a combination product (relugolix with estradiol and norethindrone) was approved for uterine fibroids based on phase 3 trials showing reduction in menstrual blood loss. The rapid reversibility of suppression upon discontinuation is a distinguishing pharmacological feature.
Oral
FDA Approved
Interested in Relugolix (Orgovyx)?
Find a verified provider experienced with Relugolix (Orgovyx) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Relugolix (Orgovyx) ProviderRelated Peptides
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S proteasome. By blocking proteasomal degradation of ubiquitinated proteins, carfilzomib causes accumulation of misfolded proteins, endoplasmic reticulum stress, and activation of the unfolded protein response, leading to apoptosis preferentially in malignant plasma cells. Its irreversible binding confers greater proteasome inhibition than bortezomib.
Bortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortezomib disrupts the ubiquitin-proteasome pathway, stabilizing pro-apoptotic factors and inhibiting NF-kB activation, which is constitutively active in many hematologic malignancies. It was the first proteasome inhibitor approved for cancer treatment and fundamentally changed the treatment landscape of multiple myeloma.
Lutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioisotope lutetium-177. Lutathera binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells, delivering targeted radiation therapy directly to tumor cells while sparing surrounding normal tissue. This peptide receptor radionuclide therapy (PRRT) approach combines receptor-targeted delivery with cytotoxic radiation.
Leuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in premenopausal breast cancer. Chronic administration produces sustained downregulation of pituitary GnRH receptors, achieving medical castration with testosterone levels below 50 ng/dL. The initial testosterone flare can be mitigated by co-administration of an antiandrogen. Depot formulations provide sustained release for up to 6 months.